Latest Earnings Results:
Estimated EPS
---
Reported EPS
---
Surprise
---
Estimated Rev
---
Reported Rev
---
Surprise
---
Champions Oncology, Inc. reported oncology revenue of $15.2M for the quarter ended July 31, 2026, compared to $14M in the prior year period, reflecting an 8.8% increase.
Bullish Takeaway
Champions Oncology, Inc. delivered revenue growth driven by strong data licensing performance and pharmacology services, while management maintains sufficient liquidity to fund core research initiatives through September 2027.
Bearish Takeaway
Champions Oncology, Inc. faces financial challenges including a persistent net loss, a large accumulated deficit, negative cash flow from operations, and uncertainty regarding the ability to secure future capital.
Generated by Stocktwits using AI and company-reported earnings data. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|